RayKnowChina Research Map
Shortlist

Not yet recruitingLymphomaPhase 2

Registered title, quoted from ClinicalTrials.gov

Glofitamab Plus Gemcitabine and Oxaliplatin (GemOx) in Relapsed or Refractory Primary and Secondary Central Nervous System Lymphoma

An open trial on lymphoma, registered on ClinicalTrials.gov. Led by Jiangsu Province Hospital; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorJiangsu Province Hospital江苏省人民医院(南医大一附院)NanjingHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07888621, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 8

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (8 points)Hide the checklist
  1. 18 years to Not stated; sex: all

    Registered eligibility fields

  2. 8. Cardiac function: New York Heart Association (NYHA) class below III; left ventricular ejection fraction >= 50% on echocardiography

    Inclusion criterion 8

  3. 12. Women of childbearing potential and male participants with a female partner of childbearing potential must use effective contraception throughout the treatment period and for 90 days after the last dose of study treatment

    Inclusion criterion 12

    3. Previous allogeneic organ transplantation or allogeneic haematopoietic stem cell transplantation

    Exclusion criterion 3

    10. Grade >= 3 immune-related adverse events during previous immunotherapy

    Exclusion criterion 10

  4. 4. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 4

    Inclusion criterion 4

  5. 6. Hepatic function: serum total bilirubin (TBIL) <= 1.5 x upper limit of normal (ULN); alanine aminotransferase (ALT) and aspartate aminotransferase (AST) <= 2.5 x ULN

    Inclusion criterion 6

    7. Renal function: serum creatinine (Cr) <= 2 x ULN, or creatinine clearance (CCR) >= 60 mL/min

    Inclusion criterion 7

    9. Coagulation function: international normalised ratio (INR) <= 1.5 x ULN, activated partial thromboplastin time (APTT) <= ULN + 10 s, and prothrombin time (PT) <= ULN + 3 s

    Inclusion criterion 9

  6. 3. Whole-body PET/CT and brain MRI (plain plus contrast) performed within 28 days before enrolment must show at least one measurable lesion in two perpendicular dimensions (according to the Lugano 2014 criteria)

    Inclusion criterion 3

  7. 2. A second primary malignancy (except non-melanoma in-situ skin cancer, superficial bladder cancer, in-situ cervical cancer, gastrointestinal intramucosal carcinoma, or breast cancer that has been cured with no recurrence within 5 years)

    Exclusion criterion 2

    9. Known active pulmonary tuberculosis

    Exclusion criterion 9

  8. 14. Pregnant or breastfeeding women

    Exclusion criterion 14

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07888621, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • 1. Histopathologically confirmed relapsed/refractory primary central nervous system lymphoma (PCNSL), or secondary central nervous system lymphoma (SCNSL) with isolated central nervous system relapse
  • 2. Written informed consent obtained, and the participant is able to comply with the protocol-specified visits and procedures
  • 3. Whole-body PET/CT and brain MRI (plain plus contrast) performed within 28 days before enrolment must show at least one measurable lesion in two perpendicular dimensions (according to the Lugano 2014 criteria)
  • 4. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 4
  • 5. Adequate organ and bone marrow function, defined as: complete blood count - absolute neutrophil count (ANC) >= 1.0 x 10\^9/L, platelet count (PLT) >= 50 x 10\^9/L, and haemoglobin (HGB) >= 8.0 g/dL; no granulocyte growth factor, platelet transfusion or red blood cell transfusion within 7 days before testing
  • 6. Hepatic function: serum total bilirubin (TBIL) <= 1.5 x upper limit of normal (ULN); alanine aminotransferase (ALT) and aspartate aminotransferase (AST) <= 2.5 x ULN
  • 7. Renal function: serum creatinine (Cr) <= 2 x ULN, or creatinine clearance (CCR) >= 60 mL/min
  • 8. Cardiac function: New York Heart Association (NYHA) class below III; left ventricular ejection fraction >= 50% on echocardiography
  • 9. Coagulation function: international normalised ratio (INR) <= 1.5 x ULN, activated partial thromboplastin time (APTT) <= ULN + 10 s, and prothrombin time (PT) <= ULN + 3 s
  • 10. Life expectancy of more than 3 months
  • 11. Age 18 years or older
  • 12. Women of childbearing potential and male participants with a female partner of childbearing potential must use effective contraception throughout the treatment period and for 90 days after the last dose of study treatment

Exclusion Criteria:

  • 1. Involvement of any site outside the central nervous system
  • 2. A second primary malignancy (except non-melanoma in-situ skin cancer, superficial bladder cancer, in-situ cervical cancer, gastrointestinal intramucosal carcinoma, or breast cancer that has been cured with no recurrence within 5 years)
  • 3. Previous allogeneic organ transplantation or allogeneic haematopoietic stem cell transplantation
  • 4. Anticipated need for any other systemic anticancer therapy during the study period
  • 5. Anti-tumour vaccine or other immunostimulatory anticancer therapy within 3 months before the first dose
  • 6. Severe acute or chronic infection requiring systemic treatment
  • 7. Human immunodeficiency virus antibody (HIV-Ab) positivity, active hepatitis, or any other uncontrolled infectious disease
  • 8. Current or prior idiopathic pulmonary fibrosis or idiopathic pneumonia
  • 9. Known active pulmonary tuberculosis
  • 10. Grade >= 3 immune-related adverse events during previous immunotherapy
  • 11. Documented history of neurological or psychiatric disorders
  • 12. Receipt of any live vaccine for infectious diseases (e.g., influenza vaccine, varicella vaccine) within 4 weeks before the first dose, or planned use during the study period
  • 13. Documented history of alcohol or drug abuse
  • 14. Pregnant or breastfeeding women
  • 15. Receipt of any other investigational active drug within 1 month before the first dose
  • 16. Any other condition that, in the investigator's opinion, may affect the efficacy or safety assessment of this study

Quoted from ClinicalTrials.gov, NCT07888621, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07888621, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07888621